Gastrointestinal Staphylococcus Lentus Composition for Insulin Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Insulin resistance and type 2 diabetes are difficult to cure, often accompanied by weight gain, impaired glucose tolerance, immune weakness, and low-grade inflammation, and the role of Staphylococcus lentus in preventing and treating these conditions is unclear.
Innovation Solution
A composition containing Staphylococcus lentus, specifically strain GDMCC 1.247, is used as a food, health care product, or drug to prevent or treat insulin resistance and type 2 diabetes, administered via the gastrointestinal tract, reducing weight gain, improving glucose tolerance, and enhancing immunity and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If strict diet control and exercise enhancement are implemented to cure insulin resistance, then insulin resistance can be cured and transformation to type 2 diabetes reduced, but patient compliance is difficult to maintain and lifestyle changes are challenging
Solution Approach 1:
The patent introduces Staphylococcus lentus as a biological intermediary that mediates the treatment of insulin resistance. Instead of relying solely on patient compliance with lifestyle changes, the bacterial strain acts as a mediator that directly influences metabolic parameters, including improving insulin sensitivity and reducing inflammation, thereby achieving therapeutic effects with reduced dependence on patient behavioral compliance
Solution Approach 2:
The patent employs probiotic bacteria that can self-replicate and persist in the gut microbiota, providing continuous therapeutic effect without requiring repeated external intervention. The bacteria serve themselves by colonizing the host and continuously producing beneficial metabolic effects, reducing the need for ongoing patient effort or medical intervention
2Reliability
If conventional treatments for insulin resistance are used, then some symptoms may be managed, but adverse reactions and safety concerns arise
Solution Approach 1:
The patent utilizes a probiotic bacterial strain that is administered as a live biotherapeutic product. The bacteria are designed to be transient yet effective, colonizing the gut temporarily to deliver therapeutic benefits and then naturally shedding, avoiding the accumulation of long-term side effects associated with conventional pharmaceuticals. This approach provides effective treatment while minimizing adverse reactions through the temporary, self-limiting nature of the probiotic intervention
Data Source
AI summary
Provided is a use of Staphylococcus lentus with an accession number of GDMCC 1.247 in preparation of a composition for preventing and treating insulin resistance or type 2 diabetes. This strain can significantly reduce the weight gain induced by a high-fat diet (HFD), improve the glucose tolerance, promote the insulin secretion, improve the insulin resistance, and significantly improve the immunity and inflammation.